All Updates

All Updates

icon
Filter
Partnerships
PostEra partners with Pfizer to accelerate small molecule drug discovery
AI Drug Discovery
Dec 7, 2020
This week:
Product updates
Nintendo ventures into MMOs with new Switch Online game playtest
Metaverse Experience Platforms
Yesterday
Product updates
HP releases texture library for 3D printing with CoreTechnologie 4D Additive
Additive Manufacturing
Oct 21, 2024
Partnerships
Honeywell partners with Google to bring Gemini AI to industrial sector
Smart Factory
Oct 21, 2024
Product updates
xAI launches API for third-party developers to access Grok models
Foundation Models
Oct 21, 2024
Partnerships
Nava Benefits partners with OpenAI to launch AI-powered benefits assistant
Foundation Models
Oct 21, 2024
Product updates
IBM releases Granite 3.0 AI models for enterprise use
Foundation Models
Oct 21, 2024
Partnerships
Honeywell partners with Google to bring Gemini AI to industrial sector
Foundation Models
Oct 21, 2024
M&A
Inflection AI acquires Boundaryless for undisclosed sum to accelerate enterprise AI deployments
Foundation Models
Oct 21, 2024
Industry news
News Corp sues Perplexity AI for alleged copyright infringement
Generative AI Applications
Oct 21, 2024
Product updates
Haiper debuts new video generation model
Generative AI Applications
Oct 21, 2024
AI Drug Discovery

AI Drug Discovery

Dec 7, 2020

PostEra partners with Pfizer to accelerate small molecule drug discovery

Partnerships

  • California-based AI drug discovery company PostEra has announced a multi-year strategic partnership with the pharma giant Pfizer to accelerate small molecule drug discovery. 

  • PostEra will develop a generative chemistry-based platform by utilizing Pfizer’s extensive data and expertise to be deployed across in-house, preclinical drug discovery programs. 

  • PostEra will receive an undisclosed upfront payment and is also eligible for additional milestone payments. Ownership rights of any algorithms developed during the partnership will belong to PostEra. 

  • Founded in 2019, PostEra is a University of Cambridge spin-out company engaged in utilizing machine learning technology to design novel molecular structures. Its approach is based on combining chemical synthesis with molecular designing. In addition to collaborating with drug developers, it also operates a chemical database, Manifold, to offer some of its synthesis technology. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.